MDPI was about to publish a special issue in one of its journals to fete the career of a retired dean. But after Retraction Watch informed the co-editors of the issue that the researcher, Kishor Wasan, had abruptly retired after being found to have plagiarized a 2019 book review for The Lancet, the publisher evidently decided to cancel the planned celebration.
The special issue of Pharmaceutics – here’s a Wayback Machine link – was to be “in honour of Professor Kishor M Wasan’s remarkable contributions to the pharmaceutics field.”
But now it is gone, and prompts a 404 error rather than any explanation.
A leading repository of social science which is owned by Elsevier has reposted an article it removed on New Year’s Day after the author was accused of defamation and the site was threatened with legal action if it didn’t remove the paper.
The article in question was written by Ann Lipton, the associate dean for faculty research at Tulane University Law School and appeared on the Social Science Research Network (SSRN).
Titled “Capital Discrimination,” the paper – which has been accepted by the Houston Law Review – explores:
The article as it appears at the time of this writing
Yes, you read that headline right.
In January 2021, we reported that The Journal of Strength and Conditioning Research (JSCR) would soon be retracting two papers because a graduate student had committed misconduct in the work.
The journal – the official research publication of the National Strength and Conditioning Association (NCSA) – did retract the papers, according to a notice posted to PubMed and on the title’s site, both dated March 2021.
A journal has issued expressions of concern for a pair of 2021 meta-analyses purporting to find that ivermectin is an effective treatment for Covid-19 after data sleuths raised questions about some of the research in the studies.
As we reported last fall, one of the two papers – “Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines” – began to wobble when data central to its conclusion were retracted from the journal Viruses. That article has been cited 37 times, according to Clarivate Analytics’ Web of Science, making it a highly-cited, “hot” paper.
The other article was titled “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19” and was written by a group led by Pierre Kory. Kory is a controversial Wisconsin physician whose ideas about how to treat the infection, and particularly ivermectin, have made him a darling of ivermectin proponents like Joe Rogan.
The two meta-analyses were the subject of an editorial in the November/December 2021 issue of the journal by its editor, Peter Manu, who cautioned that:
There’s a new entry on the Retraction Watch Leaderboard. And this one is also the fourth member of the Retraction Watch Century Club.
An anesthesiology researcher in Japan is now up to 117 retractions – putting him third on our list of most-retracted authors.
Hironobu Ueshima, formerly of Showa University Hospital in Tokyo, was found to have committed misconduct in 142 papers, according to a pair of investigations, one by his erstwhile institution and another by the Japanese Society of Anesthesiologists (JSA). We first reported on the existence of the investigation in June 2020, some three months after Australian anesthesiologist and journal editor John Loadsman raised concerns with journals involved in the case.
A Lancet journal has issued an expression of concern for a 2019 paper by a group in the United Kingdom whose work was found to have included fabricated data and other misconduct.
A lung researcher is up to six retractions for problematic images.
Dilip Shah’s last academic post was at Cooper University Hospital in Camden, N.J., where he worked as a post-doc in the lab of Vineet Bhandari. While there, Shah landed first authorship on a 2020 article in the European Respiratory Journal titled “miR-184 mediates hyperoxia-induced injury by targeting cell death and angiogenesis signalling pathways in the developing lung.”
A 2018 study in PNAS that claimed to show a biotech company’s platform for creating immunotherapies was better than existing methods has earned an expression of concern over the reproducibility of some of its findings.
The technique was developed by SQZ Biotech, which was founded by MIT’s Robert Langer, a founder or co-founder of numerous biotechs including Moderna, and with whom Roche partnered in 2015.
The paper has been cited 55 times, according to Clarivate Analytics’ Web of Science. According to a press release announcing the work:
